Company intelligence / Profile preview
Simnova Biotherapeutics
Shanghai, Shanghai, Chinaprnewswire.com ↗
- Ownership
- Private
- Development stage
- Clinical
01
Overview
Several lead programs have entered Phase I clinical trials, including allogeneic CAR-NK for B-cell malignancies, dual-targeting BCMA/GPRC5D NK cells for multiple myeloma, multi-targeted autologous CAR-Ts for glioblastoma multiforme and solid tumors. Early data show promising safety and activity in initial patient cohorts. Preclinical collaborations with Orna Therapeutics are advancing novel in vivo RNA-based cell therapies targeting BCMA.
- Therapeutic areas
- Oncology
- Modalities
- CAR-NKCAR-TOncolytic VirusesNext-gen CytokinesCancer Vaccines
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →03
Partnerships
Orna Therapeutics
Beyond the preview
Go deeper on Simnova Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Simnova Biotherapeutics.